Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib vs placebo in Progressive Supranuclear Palsy (PSP)
2013-003740-23Phase 3Terminated
- Sponsor
- AB Science
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in progressive supranuclear palsy (PSP) comparing Masitinib with Placebo (2 arms). Primary endpoint: Progressive Supranuclear Palsy Rating Scale (PSPRS) score change. Started Dec 2013; status: terminated.
02
Drugs
masitinib
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on 2013-003740-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003740-23.